Pazopanib Hydrochloride: A Comprehensive Guide to its Application and Benefits in Cancer Therapy
Discover the targeted power of Pazopanib Hydrochloride in treating complex cancers like RCC and STS.
Get a Quote & SampleProduct Core Value
Pazopanib Hydrochloride
Pazopanib Hydrochloride (HCL) is a crucial anti-cancer medication employed in targeted therapy, primarily for renal cell carcinoma (RCC) and advanced soft tissue sarcoma (STS). Its efficacy stems from its role as a multi-kinase inhibitor that disrupts tumor growth by targeting angiogenesis. The drug's mechanism of action involves inhibiting key enzymes such as vascular endothelial growth factor receptors (VEGFR), platelet-derived growth factor receptor (PDGFR), and c-KIT, thereby limiting the formation of new blood vessels essential for tumor survival and proliferation. Its recognized therapeutic value is supported by approvals from major regulatory bodies worldwide, including the FDA, EMA, MHRA, and TGA.
- Understanding the Pazopanib hydrochloride mechanism of action reveals its potent anti-angiogenic properties, crucial for inhibiting tumor progression.
- The Pazopanib hydrochloride FDA approval in 2009 marked a significant advancement in the treatment of advanced RCC and STS.
- The Pazopanib hydrochloride uses in cancer therapy extend to specific patient populations who have previously undergone chemotherapy or cytokine treatment.
- Detailed knowledge of Pazopanib hydrochloride adverse effects and drug interactions is vital for safe and effective patient management.
Key Advantages of Pazopanib Hydrochloride
Targeted Efficacy
Pazopanib hydrochloride offers targeted cancer therapy, specifically focusing on inhibiting tumor growth pathways. Research into Pazopanib hydrochloride bioavailability indicates consistent absorption for effective treatment.
Global Regulatory Acceptance
The drug boasts approvals from major regulatory bodies like the FDA and EMA, assuring its quality and safety for medical use. Understanding Pazopanib hydrochloride FDA approval criteria is key.
Broad Application Spectrum
Beyond its primary indications, ongoing studies explore the potential of Pazopanib hydrochloride in treating other forms of cancer, showcasing its versatility in oncology.
Key Applications
Renal Cell Carcinoma Treatment
Pazopanib hydrochloride is a first-line treatment for advanced RCC and is also used for patients who have received prior cytokine therapy, demonstrating significant Pazopanib hydrochloride uses in cancer therapy.
Soft Tissue Sarcoma Treatment
It is indicated for adult patients with specific advanced soft-tissue sarcoma subtypes who have progressed after prior chemotherapy, highlighting critical Pazopanib hydrochloride mechanism of action.
Oncology Research
The drug's multifaceted action makes it a subject of ongoing research for various other cancers, contributing to the broader field of targeted therapy development.
Pharmaceutical Intermediate Sourcing
For pharmaceutical companies, sourcing Pazopanib Hydrochloride requires careful consideration of Pazopanib hydrochloride drug interactions and supply chain reliability.